JP2024527109A5 - - Google Patents
Info
- Publication number
- JP2024527109A5 JP2024527109A5 JP2024505416A JP2024505416A JP2024527109A5 JP 2024527109 A5 JP2024527109 A5 JP 2024527109A5 JP 2024505416 A JP2024505416 A JP 2024505416A JP 2024505416 A JP2024505416 A JP 2024505416A JP 2024527109 A5 JP2024527109 A5 JP 2024527109A5
- Authority
- JP
- Japan
- Prior art keywords
- kras
- poziotinib
- inhibitor
- pharmaceutical product
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227237P | 2021-07-29 | 2021-07-29 | |
| US63/227,237 | 2021-07-29 | ||
| PCT/US2022/074317 WO2023010121A1 (en) | 2021-07-29 | 2022-07-29 | Methods and compositions for treatment of kras mutant cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527109A JP2024527109A (ja) | 2024-07-19 |
| JP2024527109A5 true JP2024527109A5 (cg-RX-API-DMAC7.html) | 2025-08-05 |
Family
ID=85087345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505416A Pending JP2024527109A (ja) | 2021-07-29 | 2022-07-29 | Kras変異体がんの処置のための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240374597A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4376959A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527109A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240051145A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118043075A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227802A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023010121A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN121846289A (zh) * | 2024-10-12 | 2026-04-14 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 包括nampt抑制剂和kras抑制剂的组合物及其用途 |
| CN119607214B (zh) * | 2025-02-17 | 2025-06-20 | 四川大学华西医院 | Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3112043A1 (en) * | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| MX2021010265A (es) * | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021298154A1 (en) * | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| KR102379786B1 (ko) * | 2020-08-13 | 2022-03-25 | 정부환 | 레일 형식 보행보조기구 방향전환장치 |
-
2022
- 2022-07-29 KR KR1020247006944A patent/KR20240051145A/ko active Pending
- 2022-07-29 WO PCT/US2022/074317 patent/WO2023010121A1/en not_active Ceased
- 2022-07-29 US US18/293,144 patent/US20240374597A1/en active Pending
- 2022-07-29 CN CN202280059341.9A patent/CN118043075A/zh active Pending
- 2022-07-29 JP JP2024505416A patent/JP2024527109A/ja active Pending
- 2022-07-29 EP EP22850547.5A patent/EP4376959A4/en active Pending
- 2022-07-29 CA CA3227802A patent/CA3227802A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250295869A1 (en) | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| Manic et al. | Chloroquine and hydroxychloroquine for cancer therapy | |
| De Oliveira et al. | Clinical presentation and management of mTOR inhibitor-associated stomatitis | |
| NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
| JP2019532051A5 (cg-RX-API-DMAC7.html) | ||
| AU2015326196B2 (en) | Pharmaceutical composition for treating ulcerative colitis | |
| JP2020500152A5 (cg-RX-API-DMAC7.html) | ||
| JP2023533464A5 (cg-RX-API-DMAC7.html) | ||
| JP2019510785A5 (cg-RX-API-DMAC7.html) | ||
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| IL320562A (en) | Cancer treatment methods | |
| NO20066054L (no) | behandling med cisplatin og en EGFR-inhibitor | |
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| JP2024502446A5 (cg-RX-API-DMAC7.html) | ||
| Kogure et al. | Cytokine release syndrome with pseudoprogression in a patient with advanced non–small cell lung cancer treated with pembrolizumab | |
| TW202329946A (zh) | 用於治療癌症之方法及包含cdk2抑制劑之給藥方案 | |
| KR20190018632A (ko) | Phy906 추출물, 황금(s) 추출물 또는 이러한 추출물로부터의 화합물을 포함하는 병용 요법을 이용한 항-면역 체크포인트 억제제의 개선된 치료 지수 | |
| EP4489756A1 (en) | Methods of treating small cell lung cancer | |
| NO20066080L (no) | Behandling med irinotecan (CPT-11) og en AGFR-inhibitor | |
| WO2023272831A1 (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JP2025521501A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2022260132A5 (cg-RX-API-DMAC7.html) | ||
| RU2020126340A (ru) | Способы и комбинированное терапевтическое средство для лечения рака | |
| JP2022504760A5 (cg-RX-API-DMAC7.html) |